Synergistic Ocular Delivery Systems with AI, IoT, and Blockchain Integration
Legal Citation
Summary of the Inventive Concept
The present invention combines the ocular delivery systems and methods of the original patent with advanced technologies like AI, IoT, and blockchain to create a more effective, personalized, and data-driven treatment approach for ocular conditions.
Background and Problem Solved
The original patent disclosed ocular delivery systems and methods for accessing Schlemm's canal, delivering viscoelastic fluids, and performing trabeculotomies. However, these systems lacked the ability to analyze patient-specific data, optimize treatment parameters, and integrate with wearable technology and cloud-based servers. The present invention addresses these limitations by incorporating synergistic combinations of AI, IoT, blockchain, and MEMS technologies to enhance ocular treatment outcomes.
Detailed Description of the Inventive Concept
The inventive concept comprises a fluid delivery system with an AI module that analyzes eye anatomy and optimizes fluid delivery parameters. Additionally, a blockchain-based data management system tracks and analyzes patient treatment data, enabling personalized adjustments to the fluid composition. An IoT-enabled sensor monitors intraocular pressure, and a MEMS-based actuator provides precision control of the trabeculotomy procedure. The system also includes a machine learning algorithm for predicting optimal treatment parameters based on patient-specific eye anatomy and treatment history, and a 3D printed custom implant for delivering the viscoelastic fluid composition to Schlemm's canal. Furthermore, the system integrates with wearable technology to monitor intraocular pressure and receive personalized treatment recommendations.
Novelty and Inventive Step
The present invention's novelty lies in the synergistic integration of AI, IoT, blockchain, and MEMS technologies with the original ocular delivery systems and methods. The inventive step resides in the unexpected combination of these technologies to create a more effective, personalized, and data-driven treatment approach for ocular conditions.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include the use of other AI algorithms, different IoT sensors, or alternative blockchain architectures. Additionally, the system could be adapted for use in other medical applications, such as cardiovascular or neurological treatments.
Potential Commercial Applications and Market
The present invention has significant commercial potential in the ophthalmology market, particularly in the treatment of glaucoma and other ocular conditions. The integration of AI, IoT, and blockchain technologies is expected to increase treatment efficacy, reduce costs, and improve patient outcomes. The market for ocular delivery systems is projected to grow significantly in the coming years, driven by the increasing prevalence of ocular diseases and the need for more effective treatment options.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61F9/0008 |
| A | A61 | A61F9/00781 |
| A | A61 | A61M5/002 |
| A | A61 | A61M5/158 |
| A | A61 | A61M5/3286 |
| A | A61 | A61M5/3291 |
| A | A61 | A61M2005/1585 |
| A | A61 | A61M2210/0612 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical device technologies for ophthalmic interventions, specifically ocular fluid delivery systems, microsurgical devices, and precision medical instrumentation with expertise in fluid mechanics, medical device design, and minimally invasive surgical techniques
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or medical device designer with advanced degrees in bioengineering, mechanical engineering, or medical technology, possessing knowledge of ophthalmic surgical techniques, microfluidic systems, and emerging medical technology integration strategies
Obviousness Rationale
A PHOSITA would recognize that integrating advanced digital technologies like AI, IoT, and blockchain with existing ocular delivery systems represents a predictable technological evolution. The core fluid delivery mechanism remains fundamentally consistent with the source patent, while the proposed technological enhancements represent logical extensions of known medical device optimization strategies. The proposed variations leverage standard engineering approaches to enhance monitoring, personalization, and data management in medical device technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,460 |
|---|---|
| Title | Ocular delivery systems and methods |
| Assignee(s) | Sight Sciences, Inc. |